- <![CDATA[REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer]]><![CDATA[Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.]]>onclive · 2mo ago↗ source
- AstraZeneca follows Merck with Phase 3 win in bladder cancerA combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek ap…Endpoints · 2mo ago↗ source
- MacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attackPlus, news about Bavarian Nordic and OrganaBio’s new CDMO subsidiary: 🏭 Bora buys MacroGenics' manufacturing operations: MacroGenics is selling its clinical and commercial drug substance product…